Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance-Reference-Cited by-同舟云学术

Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance

Published:2019-09-17 Issue:11 Volume:22 Page:1202-1209
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Barqawi Yazan K.¹,Borrego Matthew E.¹,Roberts Melissa H.¹,Abraham Ivo²

Affiliation:

1. College of Pharmacy, University of New Mexico, Albuquerque, NM, USA;

2. Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1661581

Reference63 articles.

1. Street W. Cancer Facts & Figures 2018. 1930;76.

2. American Cancer Society. Key Statistics for Prostate Cancer | Prostate Cancer Facts [Internet]. [March 2019]. Available at https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.

3. Lexi Comp Online. Apalutamide: Drug information - UpToDate [Internet]; [October 2018]. Available at https://www-uptodate-com.libproxy.unm.edu/contents/apalutamide-drug-information?source=see_link.

4. Graff J, Moul J. Understanding Nonmetastatic CRPC: An Overview [Internet]. [October 2018]. Available at https://www.onclive.com/insights/nonmetastatic-crpc/understanding-nonmetastatic-crpc-an-overview.

5. Characterising the castration-resistant prostate cancer population: a systematic review

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran;BMC Urology;2024-02-20

2. The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer;International Journal of Technology Assessment in Health Care;2024

3. Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews;Frontiers in Oncology;2023-09-27

4. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics;Frontiers in Oncology;2023-08-17

5. Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness Analysis;Clinical Genitourinary Cancer;2023-02